Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing